SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-041266
Filing Date
2020-02-19
Accepted
2020-02-19 06:12:40
Documents
13
Period of Report
2020-02-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d885396d8k.htm   iXBRL 8-K 33618
2 EX-99.1 d885396dex991.htm EX-99.1 9099
  Complete submission text file 0001193125-20-041266.txt   172563

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20200214.xsd EX-101.SCH 3106
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20200214_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20200214_pre.xml EX-101.PRE 11432
8 EXTRACTED XBRL INSTANCE DOCUMENT d885396d8k_htm.xml XML 3372
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 20627378
SIC: 2834 Pharmaceutical Preparations